CJC-1295 No DAC vs DAC: What the Difference Is

The short answer

"CJC-1295 no DAC" is the common trade name for modified GRF(1-29): a 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) with no drug affinity complex (DAC) attached. The original CJC-1295 carries that DAC linker. The two are different molecules, with different masses and very different published behaviour, and listings routinely blur them.

Our CJC-1295 + Ipamorelin blend uses the no-DAC form.

No DAC versus with DAC

The DAC is what makes the long-acting form long-acting. It is designed to bind serum albumin, and in a human pharmacokinetic study of the DAC form the estimated half-life was 5.8 to 8.1 days (Teichman et al.). Unmodified GHRH(1-29) is cleared in minutes. The four substitutions in the no-DAC form are there to resist enzymatic breakdown, not to add albumin binding.

Those human data describe the DAC form only. They say nothing certain about the no-DAC peptide.

Why the labels get mixed up

Retail listings often write "CJC-1295" with no qualifier, and some label the DAC form as no DAC or the reverse. Three checks settle it:

• •The name on the certificate. It should say DAC or no DAC explicitly.
• •The measured mass. A figure near 3,368 Da is the no-DAC peptide. A figure near 3,647 Da is the DAC form.
• •The batch number. The one on the vial must match the one on the report.

A listing that cannot say which form it supplies is not documenting its own material. The certificate for our blend quantifies each component separately: see batch 100245 in the COA library and the CJC-1295 + Ipamorelin 10mg product page.

What it is not

• •Sermorelin is unmodified GHRH(1-29). It has the same length but none of the substitutions.
• •Tesamorelin is a 44-amino-acid GHRH analogue. See tesamorelin: identity, regulatory status and evidence.
• •Ipamorelin acts at a different receptor and is not a GHRH analogue. Ipamorelin, CJC-1295 and Sermorelin compares all three.

Key references

• •Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536

Scope and laboratory-use boundary

Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.

We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.